Fisher Funds Management LTD Invests $96.51 Million in DexCom, Inc. (NASDAQ:DXCM)

Fisher Funds Management LTD purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,241,721 shares of the medical device company’s stock, valued at approximately $96,507,000. DexCom comprises about 2.3% of Fisher Funds Management LTD’s investment portfolio, making the stock its 12th biggest holding. Fisher Funds Management LTD owned about 0.32% of DexCom at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Creative Planning increased its stake in shares of DexCom by 22.3% in the 3rd quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock valued at $3,994,000 after buying an additional 10,880 shares during the period. Blue Trust Inc. boosted its holdings in DexCom by 101.9% in the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 898 shares during the last quarter. Private Advisor Group LLC boosted its holdings in DexCom by 5.7% in the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock valued at $759,000 after acquiring an additional 608 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in DexCom in the third quarter worth about $930,000. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in DexCom by 15.1% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 4,409 shares of the medical device company’s stock worth $296,000 after purchasing an additional 579 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $99.06.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 in the last 90 days. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

Shares of DXCM stock opened at $88.78 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company’s 50 day moving average price is $83.50 and its two-hundred day moving average price is $76.06. The company has a market capitalization of $34.69 billion, a P/E ratio of 62.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.